Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neus Llarch

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
Frontiers in Immunology|June 23, 2025
Lymphocyte exhaustion in hepatocellular carcinoma: a dynamic evolution across disease stagesCarla Fuster-Anglada, Josep Corominas, Aida Marsal, et al.
Journal of Experimental & Clinical Cancer Research : CR|January 8, 2026
Immune remodeling via mitochondria-dependent STING activation enhances cabozantinib response in hepatocellular carcinomaPatricia Rider, Anna Tutusaus, Carlos Cuño-Gómiz, et al.
Frontiers in Immunology|February 23, 2026
Correction: Lymphocyte exhaustion in hepatocellular carcinoma: a dynamic evolution across disease stagesCarla Fuster-Anglada, Josep Corominas, Aida Marsal, et al.
Journal of Clinical Gastroenterology|June 13, 2020
Pancreatic Insufficiency in Patients Under Sorafenib Treatment for Hepatocellular CarcinomaÁlvaro Díaz-González, Ernest Belmonte, Víctor Sapena, et al.
Cancers|September 14, 2024
Challenges in Liver Transplantation for Hepatocellular Carcinoma: A Review of Current ControversiesEzequiel Mauro, Marco Sanduzzi-Zamparelli, Gabrielle Jutras, et al.
Cancers|July 14, 2023
Risk of Treatment Failure and Death after Ablation in Hepatocellular Carcinoma Patients-A Multiparametric PredictionSergio Muñoz-Martínez, Victor Sapena, Ángeles García-Criado, et al.
United European Gastroenterology Journal|July 6, 2021
Early diarrhoea under sorafenib as a marker to consider the early migration to second-line drugsÁlvaro Díaz-González, Víctor Sapena, Loreto Boix, et al.
European Journal of Cancer (Oxford, England : 1990)|April 17, 2025
Cardiological adverse events in hepatocellular carcinoma patients receiving immunotherapy: Influence of comorbidities and clinical outcomesMarta Fortuny, Marta García-Calonge, Óscar Arrabal, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 6, 2020
Pharmacokinetics and pharmacogenetics of sorafenib in patients with hepatocellular carcinoma: Implications for combination trialsÁlvaro Díaz-González, Víctor Sapena, Loreto Boix, et al.
European Journal of Cancer (Oxford, England : 1990)|June 18, 2025
Corrigendum to" Cardiological adverse events in hepatocellular carcinoma patients receiving immunotherapy: Influence of comorbidities and clinical outcomes," [Eur J Cancer 2025 May 15:221:115404.]Marta Fortuny, Marta García-Calonge, Óscar Arrabal, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Frontiers in Immunology|June 23, 2025
Lymphocyte exhaustion in hepatocellular carcinoma: a dynamic evolution across disease stagesCarla Fuster-Anglada, Josep Corominas, Aida Marsal, et al.
Journal of Experimental & Clinical Cancer Research : CR|January 8, 2026
Immune remodeling via mitochondria-dependent STING activation enhances cabozantinib response in hepatocellular carcinomaPatricia Rider, Anna Tutusaus, Carlos Cuño-Gómiz, et al.
Frontiers in Immunology|February 23, 2026
Correction: Lymphocyte exhaustion in hepatocellular carcinoma: a dynamic evolution across disease stagesCarla Fuster-Anglada, Josep Corominas, Aida Marsal, et al.
Journal of Clinical Gastroenterology|June 13, 2020
Pancreatic Insufficiency in Patients Under Sorafenib Treatment for Hepatocellular CarcinomaÁlvaro Díaz-González, Ernest Belmonte, Víctor Sapena, et al.
Cancers|September 14, 2024
Challenges in Liver Transplantation for Hepatocellular Carcinoma: A Review of Current ControversiesEzequiel Mauro, Marco Sanduzzi-Zamparelli, Gabrielle Jutras, et al.
Cancers|July 14, 2023
Risk of Treatment Failure and Death after Ablation in Hepatocellular Carcinoma Patients-A Multiparametric PredictionSergio Muñoz-Martínez, Victor Sapena, Ángeles García-Criado, et al.
United European Gastroenterology Journal|July 6, 2021
Early diarrhoea under sorafenib as a marker to consider the early migration to second-line drugsÁlvaro Díaz-González, Víctor Sapena, Loreto Boix, et al.
European Journal of Cancer (Oxford, England : 1990)|April 17, 2025
Cardiological adverse events in hepatocellular carcinoma patients receiving immunotherapy: Influence of comorbidities and clinical outcomesMarta Fortuny, Marta García-Calonge, Óscar Arrabal, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 6, 2020
Pharmacokinetics and pharmacogenetics of sorafenib in patients with hepatocellular carcinoma: Implications for combination trialsÁlvaro Díaz-González, Víctor Sapena, Loreto Boix, et al.
European Journal of Cancer (Oxford, England : 1990)|June 18, 2025
Corrigendum to" Cardiological adverse events in hepatocellular carcinoma patients receiving immunotherapy: Influence of comorbidities and clinical outcomes," [Eur J Cancer 2025 May 15:221:115404.]Marta Fortuny, Marta García-Calonge, Óscar Arrabal, et al.
Pageof 3